期刊
NEURODEGENERATIVE DISEASES
卷 10, 期 1-4, 页码 257-260出版社
KARGER
DOI: 10.1159/000334285
关键词
Genetics; Parkinsonism; SNCA; PRKN; LRRK2; GBA; eIF4G1; VPS35
资金
- NINDS NIH HHS [1RC2NS070276, R01 NS057567, P50NS072187, P50NS072187-01S2, P50 NS072187, RC2 NS070276, NS057567] Funding Source: Medline
Background: Major progress in genetic studies of Parkinson's disease (PD) and parkinsonism has been achieved in the last two decades. Objective: We provide a brief review of the current status of PARK and non-PARK loci/genes, and discuss two new genes: eIF4G1 and VPS35. Methods: The literature on PARK and non-PARK loci/genes was reviewed and some novel information on two new genes is provided. Results: There are 18 PARK loci. The symptomatic carriers of these genes usually present with parkinsonism, although additional clinical features can be seen during the course of the disease. Carriers of non-PARK loci/genes frequently present with a mixed phenotype that includes parkinsonism and additional clinical features. Carriers of the eIF4G1 and VPS35 genes present with a parkinsonian phenotype. The pathology of eIF4G1 is of the alpha-synuclein type; the pathology of VPS35 is unknown. Conclusion: The current genetic classification of PD/parkinsonism genes is not ideal. The pathological classification based on the accumulation of particular proteins/inclusions is also misleading since there are kindred with a single mutation but pleomorphic pathology. A better classification of neurodegenerative conditions is needed. It is hoped that the genetic studies will lead to better therapies. Copyright (C) 2012 S. Karger AG, Basel
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据